| Monocytes in bone marrow |
Bisphosphonate |
Alendronate-bearing ionizable lipid (one-pot assembly) |
X, bone targeting |
64
|
| Bone marrow mesenchymal stem cells |
Bone homing peptide |
Ionizable lipid having a head group of BHODA (or HODA or ODA) (one-pot assembly) |
Osteoporosis |
97
|
| Langerhans cells, dermal DCs, and resident DCs in the skin-draining lymph node |
Mannose (intradermal) |
Man-cholesterolamine |
Influenza virus |
65
|
| LSEC |
Mannose |
DSPE-PEG-mannose and then ApoE mixing |
X, liver targeting |
66
|
| CD209/DC-SIGN and CD207/Langerin (human and mouse DCs and other hematopoietic cell populations) |
Mannose |
TriMN-Lip, MN-Lip, 1-O-carboxyl-2-O-phytanyl-3-O-hexadecane-sn-glycerol, the O,O-dioleyl-N-[3N-(N-methylimidazolium iodide)propylene] phosphoramidate, O,O-dioleyl-N-histamine phosphoramidate, and PEG-HpK |
Tumor |
98
|
| Invariant natural killer T cells |
α-Galactosylceramide |
α-Galactosylceramide (replacement) |
Tumor (melanoma) |
99
|
| Dendritic cells in a lymph node after SC |
Mannose |
PEG-mannose |
Tumor (melanoma) |
100
|
| Dendritic cells |
Mannose analogues |
Mannose analogues |
Tumor (melanoma) |
101
|
| Dendritic cell |
Mannose |
PEG-HpK and TriManlipo100 |
Tumor (melanoma) |
103
|
